A sponsor submits a dataset package to the FDA, and three weeks later the review team sends back a technical rejection. Not because the drug data was wrong. Because the SDTM domains and the ADaM datasets didn’t speak the same language the agency’s reviewers expected them to speak. This happens more often than most clinical […]